Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Virology

Background:

• Thiocarbamates (TCs) represent a novel class of non-nucleoside inhibitors targeting HIV-1 Reverse Transcriptase (RT).
• Understanding the molecular interactions between TCs and RT is crucial for developing effective antiretroviral therapies.

Purpose of the Study:

• To elucidate the atomic-level interactions between thiocarbamates and HIV-1 RT.
• To identify critical structural features influencing the antiretroviral activity of TCs.
• To guide the design of new TC-based drugs with enhanced potency, including against resistant HIV-1 mutants.

Main Methods:

• Employed molecular docking to predict binding modes of TCs within the HIV-1 RT active site.
• Utilized Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) for 3D-Quantitative Structure-Activity Relationship (3D-QSAR) studies.
• Correlated 3D-QSAR field contributions with structural features of the RT binding pocket.

Main Results:

• Developed a predictive CoMFA model (r(2)=0.93, r(cv)(2)=0.53, r(test)(2)=0.70) elucidating RT/TC interactions.
• Identified key structural determinants governing TC efficacy against HIV-1 RT.
• Demonstrated a strong correlation between 3D-QSAR descriptors and the RT binding site's structural characteristics.

Conclusions:

• Computational analyses provide atomic-level insights into thiocarbamate inhibition of HIV-1 RT.
• The findings facilitate structure-based design of next-generation thiocarbamate antiretrovirals.
• This approach is valuable for developing drugs effective against drug-resistant HIV-1 variants.